Compounded semaglutide
Direct answer
What you need to know
Evidence strength: Strong“Compounded” is not a grade, a generic, or a brand. It is a legal category — it describes who made the preparation and under which law, not how good it is. A compounded product may contain the same molecule as the approved one, but no agency has reviewed that preparation for potency, purity or quality. That is the whole difference, and it is also the reason for the price.
Key takeaways
- Compounding is lawful and long-established. It is not a loophole, and it is not the grey market.
- A compounded product is not a generic. A generic is approved and proven equivalent; this is neither.
- The FDA declared the semaglutide shortage resolved on 21 February 2025, which ended the basis for compounding copies at scale.
- What no agency has reviewed is the vial itself — its concentration, its purity, what else is in it.
- Anything sold without a prescription is not compounding at all, whatever the label says.
Important limitation: We cannot tell you whether a specific pharmacy’s product is good. Nobody outside that pharmacy can, which is the point — the review that would answer it is exactly the review a compounded preparation has not had.
Next action: If cost is what brought you here, compare it against every other route on the cheapest-routes comparison before assuming compounded is the cheapest. If you are already using one, the reconstitution guide is the page that matters most.
Primary sources: U.S. Food & Drug Administration, U.S. Food & Drug Administration
General education, not medical advice, and not a recommendation for or against compounded products.
Four routes, and what has actually reviewed each
The word people reach for is “cheaper”. The word that actually distinguishes these is reviewed — and by whom, of what.
| Route | Made under | What has been reviewed | What has not |
|---|---|---|---|
| FDA-approved product | Manufacturer, under an approved New Drug Application | Safety, efficacy and manufacturing quality reviewed by the FDA for this exact product, at these exact strengths | — |
| 503A compounded | State-licensed pharmacy, filling one patient-specific prescription | The pharmacy is licensed and overseen by its state board of pharmacy | The preparation itself is not FDA-approved. No agency has reviewed its safety, efficacy or potency. |
| 503B outsourcing facility | Facility registered with the FDA, compounding at scale | The facility registers with the FDA and must follow current good manufacturing practice, and is subject to inspection | The preparation itself is still not an FDA-approved drug, and is not reviewed product by product. |
| Sold without a prescription | No pharmacy, no prescriber — often labelled “research use only” | Nothing | No licensing, no oversight, and no way to know what is in the vial or at what concentration. |
A compounded vial may hold the same molecule as an approved one. What it does not hold is the evidence that this particular vial contains what the label says, at the strength the label says.
Why the rules changed, and what that means for what you can buy
Compounded semaglutide became widely available for a specific reason: the approved product was in shortage. While a drug sits on the FDA’s shortage list, compounders may make what amounts to a copy of it, which would otherwise not be permitted.
The FDA declared the semaglutide injection shortage resolved on 21 February 2025. It then set dates after which it would no longer decline to act against compounders on that basis:
- 22 April 2025 for state-licensed pharmacies and physicians compounding under section 503A;
- 22 May 2025 for outsourcing facilities under section 503B.
Both dates applied specifically to products that are essentially a copy of an FDA-approved drug. That phrase is the whole hinge. Compounding that is genuinely patient-specific — a preparation an individual patient needs that no approved product provides — sits under a different provision and did not end on those dates. It is why compounded products are still offered, and why the honest answer to “is it legal” is about what was made and for whom rather than a simple yes or no.
The regulatory position has kept moving since, including a 2026 proposal affecting the bulk-supply channel. The current state of that, with dates and sources, is on the provider directory, which is where we keep it because it is what decides which listed services can offer what.
What this does not tell you
It would be convenient to end with a rule — compounded is fine, or compounded is dangerous. Neither is true, and the honest position is less satisfying:
- A compounded preparation is not automatically unsafe. Compounding is a legitimate practice performed by licensed pharmacies every day, for many drugs.
- It is also not verified. No agency has confirmed that a given vial contains what it says at the strength it says. With a medication dosed in milligrams from a multi-dose vial, that gap has a practical edge — see what a vial label does and does not tell you.
- The savings are real, and so is what they buy. Compare the full monthly totals against the approved products priced the same way, where membership fees are added to medication rather than advertised separately.
That last comparison is worth doing before you commit to a compounded programme rather than after, because for this molecule it no longer lands where most people expect. The approved tablet comes in under all but one of the compounded totals we have been able to derive, and it has been through the review process that a compounded vial has not.
The line that actually matters
- A prescription is the dividing line. Lawful compounding of either kind starts with a prescriber who assessed you. A site that sells without one is not a compounding pharmacy, whatever it calls itself.
- “Research use only” is not a compounded medicine. It is the phrase that appears when a product is sold outside the medical system entirely — see what that actually means.
- Tell any prescriber what you are actually taking, including that it is compounded and at what concentration. They cannot advise on a preparation they do not know the strength of.
Questions people ask
What is compounded semaglutide?
Semaglutide prepared by a pharmacy rather than manufactured by the company that holds the approval. Compounding is a long-established, lawful practice with its own section of federal law, and it exists so that pharmacies can make a preparation a particular patient needs that no approved product provides. What it is not is a generic: a generic is an approved product proven equivalent to the original, and no compounded semaglutide has been through that.
Is compounded semaglutide legal?
Compounding itself is legal. What changed is the basis for compounding it at scale. While semaglutide was on the FDA drug shortage list, compounders could make what amounted to copies of the approved product. The FDA declared that shortage resolved on 21 February 2025, and set dates after which it would no longer decline to act on that basis — 22 April 2025 for state-licensed pharmacies and 22 May 2025 for outsourcing facilities. Compounding that is genuinely patient-specific rather than a copy sits under a different provision, which is why compounded products are still offered.
Is compounded semaglutide the same as Ozempic or Wegovy?
No. It may contain the same active molecule, but the preparation itself has not been reviewed by the FDA for safety, potency or quality, and it may differ in concentration, in what else is in the vial, and in how it is measured out. Those differences are the reason our reconstitution guide exists.
Why is compounded semaglutide cheaper?
Because it is not the approved product and carries none of the costs attached to being one — the trials, the approval, the manufacturing oversight of that specific preparation. The saving is real. What you are buying with it is the part of the price that pays for the review.
How do I know a compounded product is from a legitimate pharmacy?
The clearest signal is upstream of the vial: a legitimate route requires a prescriber who assessed you first. Anything sold without a prescription — including products labelled for research use — is not compounding under either provision, whatever the molecule on the label. Our provider directory records which services use compounded products and in whose words.
Sources
Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilizeU.S. Food & Drug AdministrationSupports: That the FDA declared the semaglutide injection shortage resolved on 21 February 2025, and the enforcement dates that followed: 22 April 2025 for 503A pharmacies and 22 May 2025 for 503B outsourcing facilities, in each case for products that are essentially a copy of an approved drug.
- Drug approvals, labeling and safety communicationsU.S. Food & Drug AdministrationSupports: The 503A and 503B compounding provisions of the Food, Drug, and Cosmetic Act, and what FDA approval does and does not cover.
- FDA-approved prescribing information (drug labels)DailyMed, U.S. National Library of MedicineSupports: The approved products a compounded preparation is being compared against, and the labelling those products carry.
This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.